title: Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.
abstract: Fifty-seven patients with MAGE-3-positive measurable metastatic cancer, most of them with melanoma, were vaccinated with escalating doses of a recombinant MAGE-3 protein combined with a fixed dose of the immunological adjuvant SBAS-2, which contained MPL and QS21. The immunisation schedule included 4 intramuscular (i.m.) injections at 3-week intervals. Patients whose tumour stabilised or regressed after 4 vaccinations received 2 additional vaccinations at 6-week intervals. The vaccine was generally well tolerated. Among the 33 melanoma patients who were evaluable for tumour response, we observed 2 partial responses, 2 mixed responses and 1 stabilisation. Time to progression in these 5 patients varied from 4 to 29 months. In addition, a partial response lasting 10 months was observed in 1 of the 3 metastatic bladder cancer patients included. None of the tumour responses described above involved visceral metastases. Immunological responses to the vaccine will be reported separately.
authors.affiliation: Ludwig Institute for Cancer Research, Brussels Branch, Brussels, Belgium. marie.marchand@bru.licr.org
authors.forename: M
authors.initials: M
authors.lastname: Marchand
authors.forename: C J A
authors.initials: CJ
authors.lastname: Punt
authors.forename: S
authors.initials: S
authors.lastname: Aamdal
authors.forename: B
authors.initials: B
authors.lastname: Escudier
authors.forename: W H J
authors.initials: WH
authors.lastname: Kruit
authors.forename: U
authors.initials: U
authors.lastname: Keilholz
authors.forename: L
authors.initials: L
authors.lastname: Håkansson
authors.forename: N
authors.initials: N
authors.lastname: van Baren
authors.forename: Y
authors.initials: Y
authors.lastname: Humblet
authors.forename: P
authors.initials: P
authors.lastname: Mulders
authors.forename: M-F
authors.initials: MF
authors.lastname: Avril
authors.forename: A M M
authors.initials: AM
authors.lastname: Eggermont
authors.forename: C
authors.initials: C
authors.lastname: Scheibenbogen
authors.forename: J
authors.initials: J
authors.lastname: Uiters
authors.forename: J
authors.initials: J
authors.lastname: Wanders
authors.forename: M
authors.initials: M
authors.lastname: Delire
authors.forename: T
authors.initials: T
authors.lastname: Boon
authors.forename: G
authors.initials: G
authors.lastname: Stoter
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000628:therapy; D005260:Female; D006801:Humans; D007114:Immunization; D008050:Lipid A / Q000008:administration & dosage / Q000031:analogs & derivatives; D008175:Lung Neoplasms / Q000628:therapy; D008297:Male; D008545:Melanoma / Q000628:therapy; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000008:administration & dosage*; D009369:Neoplasms / Q000473:pathology / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage; D012503:Saponins / Q000008:administration & dosage; D012878:Skin Neoplasms / Q000628:therapy; D016019:Survival Analysis; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000628:therapy
chemical_list: D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D008050:Lipid A; C072013:MAGEA3 protein, human; D009363:Neoplasm Proteins; D011994:Recombinant Proteins; D012503:Saponins; C472719:adjuvant SBAS-2